BridgeBio Pharma, Inc. - Common Stock (BBIO)

Bridgebio Pharma is a biotechnology company focused on developing innovative therapies for genetic diseases and cancers

The company employs a collaborative approach, partnering with academic institutions and other organizations to advance its research and development efforts. Bridgebio aims to address significant unmet medical needs by leveraging its expertise in drug discovery and clinical development, with a portfolio that includes targeted therapies and programs designed to tackle fundamental genetic abnormalities. Through its commitment to scientific innovation, Bridgebio strives to improve patient outcomes and contribute to the future of precision medicine.